-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40

Benzinga·09/21/2026 17:48:17
语音播报
Leerink Partners maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform and raises the price target from $36 to $40.